Finoriq research workspace
Anixa Biosciences Inc (ANIX) SEC Filings & Filing Highlights
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are. Review ANIX SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
- Company
- Anixa Biosciences Inc (ANIX)
- Ticker
- ANIX
- Market Cap
- $117.7M
- Latest Price
- $3.4599
- Industry
- Biotech & Pharma
Anixa Biosciences Inc (ANIX) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Anixa Biosciences Inc (ANIX).
| Event | Form | Date |
|---|---|---|
| Regulation FDRegulation FD | 8-K7.01 | 2026-03-11 |
| On March 10, 2026, Anixa Biosciences, Inc. completed its 2026 annual meeting of stockholders. T...On March 10, 2026, Anixa Biosciences, Inc. (the “Company”) completed its 2026 annual meeting of stockholders (the “Annual Meeting”). The nu... | 8-K5.07 | 2026-03-11 |
| Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Tri...Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Ma... | 8-K7.01 | 2026-02-09 |
| Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Pr...Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response... | 8-K7.01 | 2025-12-12 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.